Silent Heart Attack Market Research
Report: By Diagnosis (CT, MRI, ECG, Blood Tests), Treatment (Medications,
Coronary Angioplasty And Stenting, Coronary Artery Bypass Surgery), End User
(Hospital, Clinic, Diagnostic Center) - Global Forecast till 2023
Market Synopsis of the Global Silent
Heart Attack Market
The market for silent heart attack is
driven by rising prevalence of chronic diseases such as cardiovascular
diseases, diabetes, and others. Furthermore, changing lifestyle, and increasing
demand for diagnosis devices for cardiovascular diseases. However, limited
number of trained personnel has restrained the growth of market. However, high
cost of diagnosis and treatment of cardiovascular diseases also restrains the
growth of the market.
The global silent heart attack market is
expected to grow at a CAGR of 5.7% during the forecast period.
According to the Center for Disease
Control and Prevention (CDC), as of 2012, nearly half of all adults 117 million
population in the U.S. had one or more chronic health conditions. One in four
adults were diagnosed with two or more chronic health diseases. Cardiovascular
diseases, and diabetes are increasing the economic burden of various developing
and developed nations across the globe.
Silent heart attack usually does not have
any symptoms. The patient may experience chest pain, shortness of breath and
cold sweats. It is mostly misunderstood as indigestion, nausea, and other
common diseases. The silent
heart attack is usually caused due to various factors such as smoking or
chewing tobacco, high cholesterol, high blood pressure, diabetes, and obesity.
Risk of silent heart attack increases with an increase among the diabetic
population and people addicted to smoking. Various imaging tests such as
Cardiac Computerized Tomography, Magnetic Resonance Imaging (MRI),
electrocardiogram, echocardiogram, blood tests, and others.
Segments
The global silent heart attack market is
segmented on the basis of diagnosis, indication, devices, and end user.
On the basis of diagnosis, market is
segmented into cardiac computerized tomography, magnetic resonance imaging,
electrocardiogram, echocardiogram, blood tests, and others.
On the basis of indication, the market is
segmented into medications, coronary angioplasty and stenting, coronary artery
bypass surgery, and others.
On the basis of end user, the market is
segmented into hospitals, clinics, diagnostic centers, and others.
Key Players in the Global Silent Heart
Attack Market
Some of the key players in this market are
Siemens (U.S.), Schiller AG, Midmark Corporation, Koninklijke Philips N.V.
(Japan), Bionet (Korea), Welch Allyn (U.S.), Toshiba Medical Systems
Corporation (Japan), AstraZeneca plc (U.K), Pfizer (U.S.), Sanofi (France),
Merck & Co. (U.S.), Daiichi Sankyo Company Limited, Novartis AG (Germany),
Bayer (Germany), Takeda Pharmaceutical Company Limited (Japan), Boehringer
Ingelheim GmbH (Germany), Astellas Pharma Inc. (Japan), Johnson & Johnson
(U.S.), United Therapeutics Corporation (U.S.), Actelion Pharmaceuticals Ltd.
(Switzerland) and F. Hoffmann-La Roche Ltd (Switzerland).
Regional Analysis of the Global Silent
Heart Attack Market
America accounts for the largest market
for the silent heart attack. Increasing prevalence of cardiovascular diseases,
and diabetes is the major driving factor for the growth of the market.
According to Center of Diseases Control and Prevention (CDC), 9.3% of the total
America population is suffering from diabetes. Increasing diabetic and obese population,
rising demand for the better treatment for the diseases and well developed
infrastructure has provided fuel for the growth of the market. North America
accounts for the major share in the American silent heart attack market.
Europe accounts for the second largest
market due to a well-developed healthcare sector, continuously increasing
patient population and high healthcare expenditure. Additionally, increasing
prevalence of diabetes in the European Union (EU) also fuels the market growth.
Germany, U.K and France hold the first, second and third position in the
market.
Asia Pacific is expecting the fastest
growth for this market. Increasing prevalence of cardiovascular diseases and
rapid developments in the healthcare infrastructure are the major driving
factors for the growth of the market. India and China are the two major regions
with the highest contribution to the market growth owing to the highest
diabetic population, and increasing presence of heart attack among these
patients. Additionally, rising geriatric population further drive the growth of
the market.
In the Middle East & Africa, the
market is expected to show steady growth due to the evolving healthcare system,
and increasing demand for diagnostic and treatment services. The Middle East is
the major contributor for the market which is driven by presence of well
developed economies like Kuwait and Qatar. Whereas, Africa exhibits slow growth
due to limited development in the field of medical science and presence of poor
economic conditions in various developing regions of Africa.
Top 5 Reasons to Get this Report:
Company
profiling with detailed strategies, financials, and recent development
activities
Market
Strategic Business Influence Data
Market
Research Future recommendations in key business segments based on the market
estimations
Market
share analysis of the top industry players
Market
forecasts for a minimum of 5 years of all the mentioned segments, Trends and
the regional markets With SWOT Analysis
Browse More
Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
